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Abstract
A computational challenge to validate the candidate disease genes identified in a high-throughput genomic
study is to elucidate the associations between the set of candidate genes and disease phenotypes. The
conventional gene set enrichment analysis often fails to reveal associations between disease phenotypes
and the gene sets with a short list of poorly annotated genes, because the existing annotations of disease
causative genes are incomplete. We propose a network-based computational approach called rcNet to
discover the associations between gene sets and disease phenotypes. Assuming coherent associations
between the genes ranked by their relevance to the query gene set, and the disease phenotypes ranked
by their relevance to the hidden target disease phenotypes of the query gene set, we formulate a learning
framework maximizing the rank coherence with respect to the known disease phenotype-gene associations.
An efficient algorithm coupling ridge regression with label propagation, and two variants are introduced
to find the optimal solution of the framework. We evaluated the rcNet algorithms and existing baseline
methods with both leave-one-out cross-validation and a task of predicting recently discovered disease-
gene associations in OMIM. The experiments demonstrated that the rcNet algorithms achieved the best
overall rankings compared to the baselines. To further validate the reproducibility of the performance, we
applied the algorithms to identify the target diseases of novel candidate disease genes obtained from recent
studies of GWAS, DNA copy number variation analysis, and gene expression profiling. The algorithms
ranked the target disease of the candidate genes at the top of the rank list in many cases across all the
three case studies. The rcNet algorithms are available as a webtool for disease and gene set association
analysis at http://compbio.cs.umn.edu/dgsa_rcNet.
Author Summary
Introduction
Determination of the molecular cause of diseases is a major focus in genomics research since early 1960s [1].
Recently, powered by the advanced high-throughput genomic technologies, numerous large-scale genome-
wide disease studies such as genome-wide association studies [2,3], DNA copy number detections [4], and
gene expression profiling [5], were conducted towards this goal. Typically, the objective of a study is to
perform a high-throughput scanning for a list of genes that are involved with the disease under study,
and then a standard follow-up enrichment analysis or its variants and extensions is applied to analyze
the gene set, based on the statistical significance of the overlap between the genes and gene functional
annotations or associations with disease phenotypes. Examples of the well-known tools are DAVID [6],
GSEA [7], GOToolBox [8] and many others. However, in many cases, since the existing annotations of
disease causative genes is far from complete [1], and a gene set might only contain a short list of poorly
annotated genes, enrichment-based approaches often fail to reveal the associations between gene sets and
disease phenotypes.
The availability of large phenotypic and molecular networks provides a new opportunity to study the
association between diseases and the gene sets identified from the high-throughput genomic studies. The
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2human disease phenotype network [9] provides information on phenotype similarities computed by text
mining of the full text and clinical synopsis of the disease phenotypes in OMIM [1]. Large molecular
networks such as the human protein-protein interaction network [10] or functional linkage network [11]
provide functional relations among genes or proteins. Based on the observation that genes associated with
the same or related diseases tend to interact with each other in the gene network, many network-based
approaches are proposed to utilize the disease modules and gene modules in the networks to prioritize
disease genes, a task of ranking genes for studying genetic diseases [10–16].
In this paper, we propose a general network-based approach to infer associations between disease
phenotypes and gene sets, utilizing the disease phenotype network and the gene network. We formulate
the problem as a gene set query problem. By querying the networks with a given gene set, a user
expects to retrieve a list of disease phenotypes with the highest predicted association with the gene
set. Based on the assumption that the genes ranked by their relevance to the query gene set will have
coherent associations with the disease phenotypes ranked by their relevance to the hidden target disease
phenotypes, we formulate a simple learning framework maximizing Rank Coherence in Networks (rcNet)
with respect to the known disease phenotype-gene associations in OMIM. Fig. 1 illustrates the general
idea of Rank Coherence in Networks. We first measure the global relevance between the query gene set
and all the genes with graph Laplacian scores (Fig. 1A&B). The Laplacian scores can be considered
as the result of using the query gene set as the seed to perform random walk with restart (or label
propagation) in the gene network [17]. The global relevance between a target disease phenotype and all
disease phenotypes can be similarly computed as the Laplacian scores with random walk on the disease
phenotype network (Fig. 1D). Our assumption is that, between the rankings given by the query gene
set and the target disease phenotype, the top-ranked genes and the top-ranked phenotypes should be
highly connected by known associations, quantified by Rank Coherence in Networks (Fig. 1C). In a real
problem, the target disease phenotypes are unknown. The rcNet algorithms are designed to search for the
phenotype(s) with the best rcNet score against the query gene set. We propose two strategies. The first
approach relaxes the combinatorial problem as ridge regression to find a closed-form solution for selecting
the target disease phenotype. The second approach in two variants enumerates all possible phenotype
configurations to find the best match of the query gene set.
The rcNet algorithms are different from the gene set enrichment analysis with statistical methods
such as Hypergeometric statistics, permutation test or non-parametric McNemar’s test [6–8] because the
rcNet algorithms use the topological information in the disease phenotype network and the gene network
to analyze the association between a gene set and all phenotypes simultaneously. The simultaneous
analysis of all phenotypes provides a global dependence, and thus richer and more reliable information
for computing the association scores are used to rank the phenotypes. The rcNet algorithms share more
algorithmic similarity with the disease gene prioritization methods, which were proposed for a different
purpose. CIPHER [10] scores each gene against a disease phenotype based on the correlation between
their relevances with all the phenotypes, where the relevance between the gene and a phenotype is
calculated based on the distance between the gene and the genes associated with the phenotype. The
methods proposed by [13], [15] and [11] applied random walk (label propagation) or simpler neighborhood
weighting to exploit the gene networks for ranking genes for a disease phenotype, based on the seed genes
mapped from the disease phenotype. One limitation is that the phenotype network and the sparse known
associations are not fully utilized in the global analysis. The label propagation algorithms proposed
by [14] and [16] explore a heterogeneous network combining the gene network, the phenotype network
and the associations to explore gene modules, phenotype modules and the phenotype-gene association
biclusters. Since the two methods make full use of the information in the networks, it is difficult to
interpret the results and to tune the best parameters for combining the information.
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Figure 1. Illustration of Rank Coherence in Networks. A query gene set of four genes is given
in (A). The four genes are mapped in the gene network and the corresponding nodes are marked with 1
in (B). The graph Laplacian scores are then computed to quantify the relevance between each gene
(including the query genes) and the query gene set. Similarly, if a disease phenotype of the gene set is
selected and marked with 1, the graph Laplacian scores can be derived to quantify the relevance
between each disease phenotype and the selected phenotype in (D). Based on the coherence
assumption, the top-ranked genes and the top-ranked phenotypes should be highly connected with each
other if the phenotype is the target of the query gene set, otherwise the connectivity will be close to
random. As showed in (C), the edges connecting associated genes and phenotypes are labeled by the
discrepancy between their ranking scores. Clearly, the phenotype ranking given by target phenotype
query is more coherent (the upper case) than the ranking given by an unrelated phenotype (the bottom
case). The connectivity is measured by Rank Coherence in the Networks (rcNet). In general, since the
target disease phenotypes are not known, the rcNet algorithms search for the phenotype with the best
rcNet score against the query gene set.
4dgsa rcNet(g, G¯, P¯,A, α, β)
1 p = 0
2 g˜ = (1− α)(I− αG¯)−1g (equation (3)).
3 A¯ = (1− β)A(I− βP¯)−1
4 p∗ = (A¯TA¯ + κI)−1A¯Tg˜
5 p(p∗ > a) = 1 (target selection with
threshold a)
6 return (p)
Figure 2. rcNet Algorithm - Rank Coherence in Networks.
Methods
Problem Definition
We formulate a graph query problem for disease phenotype and gene set association discovery: given a
heterogenous network consisting of the gene network, the phenotype network and the association network,
we query the network with a gene set to retrieve a phenotype (or several) predicted to have association
with the query gene set. We define G(n×n), P(m×m), and A(n×m) as the adjacency matrix of the gene
network, the disease network, and the disease-gene association network, respectively, where n is the
number of genes and m is the number of disease phenotypes in the networks. The query gene set is
represented by a binary vector g = [g1,g2, ...,gn]
T denoting the gene membership against the gene set,
i.e. each gi = 1 if gene i is in the query gene set, otherwise 0. Similarly, the list of target phenotype(s)
is given by another binary vector p = [p1,p2, ...,pm]
T and phenotype j is a target phenotype if pj = 1.
Our objective is to find the p that gives the best rank coherence with the query gene set g.
Computing Graph Laplacian Scores
To fully utilize network topological information, we compute the global relevance score between the query
gene set g and all the genes based on the graph Laplacian of the gene network G(n×n). We first normalize
G as G¯ = D
1
2
GGD
1
2
G, where DG is a diagonal matrix with diagonal elements DGi,i =
∑
j Gi,j. A vector
g˜ of graph Laplacian scores is derived from the following optimization problem [18],
ming˜
∑
i,j
G¯i,j(g˜i − g˜j)2 + 1− α
α
∑
i
(g˜i − gi)2 (1)
In equation (1), the first term is a smoothness penalty, which forces connected genes to receive similar
scores, and the second term ensures the consistency with the query gene set. The Laplacian scores
combine the neighboring information in the network with the consistency with the query gene set to
provide a global relevance measure between each gene and the query gene set. Parameter α ∈ (0,1)
balances the contributions from the two penalties. The closed-form solution of equation (1) is
g˜ = (1− α)(I− αG¯)−1g. (2)
5Empirically, to avoid computing the inverse of (I− αG¯), an iterative algorithm can efficiently compute
the closed-form solution with the following update rule at each time step t,
g˜t = (1− α)g + αG¯g˜t−1, (3)
Similarly, graph Laplacian scores can be derived to measure the relevance between the phenotypes and
the target phenotypes p with optimization of
minp˜
∑
i,j
P¯i,j(p˜i − p˜j)2 + 1− β
β
∑
i
(p˜i − pi)2, (4)
with the closed-form solution
p˜ = (1− β)(I− βP¯)−1p, (5)
where P¯ is the normalized P and β ∈ (0,1) is the balancing parameter. Computing the laplacian scores is
equivalent to a weighted summation of performing random walk on the graph with all the steps to infinite.
Thus, the laplacian scores exploit modular information in a network to capture long range interactions
between the nodes in a graph. Note that one can use other scoring functions such as counting the direct
neighbors of the query gene set, or measuring the shortest path from the query gene set to other genes
as suggested in [10]. However, empirically, the direct-neighbor function tends to generate very sparse
information, and the shortest-path function does not fully explore the neighborhood information.
Rank Coherence in Networks
Rank Coherence in Networks (rcNet) measures whether the query gene set g and a phenotype set p show
coherent associations with the known disease-gene associations. Specifically, given the graph Laplacian
scores g˜, which rank the genes by their relevance to the query gene set g, and the graph Laplacian
scores p˜, which rank the disease phenotypes by their relevance to the hidden target phenotypes p, Rank
Coherence in Networks rcNet(g˜, p˜,A) measures whether the associations given by A are connecting
genes and phenotypes with similar scores in g˜ and p˜. We propose two different approaches to define
Rank Coherence in Networks. The first approach adopts a ridge regression model coupled with label
propagations to compute a closed-form solution of p, relaxed to real numbers. The second approach uses
simpler measures and enumerate all possible p to find the best fitting for g.
A Ridge Regression Model
Under the assumption that the Laplacian score of a phenotype can be reconstructed by the linear com-
bination of the Laplacian scores of its gene neighbors in A, we can formulate the following least-square
cost function,
Ω = ||Ap˜− g˜||2. (6)
Eventually, we are interested in deriving p. After replacing g˜ with equation (2) and p˜ with equation (5),
we have the following regularization framework,
Ω(p) = ||(1− β)A(I− βP¯)−1p− (1− α)(I− αG¯)−1g||2 + κ||p||2, (7)
where ||p||2 is a 2-norm regularizer and κ is a small constant. Equation (7) takes the standard form of
ridge regression, and thus the closed-form solution p∗ can be derived by
p∗ = (1− α)(A¯TA¯ + κI)−1A¯T(I− αG¯)−1g. (8)
where A¯ = (1− β)A(I− βP¯)−1. Note that the solution p∗ is a real vector, which can be seen as an
approximation of the binary vector p. A simple post-processing is to select one or a few phenotypes
that are assigned with significantly larger scores as the phenotypes associated with the gene set. The full
algorithm to solve the ridge regression model is given in Fig. 2. The steps at line 2, 3 and 4 require cubic
matrix inversion algorithms. Thus, the time complexity of rcNet algorithm is O(m3 + n3).
6dgsa rcNet enu(g, G¯, P¯,A, α, β)
1 g˜ = (1− α)(I− αG¯)−1g
2 p = 0, s = 0
3 for i = 1 to n
4 pi = 1
5 p˜ = (1− β)(I− βP¯)−1p.
6 si = corr(Ap˜, g˜) or
−∑i,j Ai,j(p˜i − g˜j)2
7 pi = 0
8 j = argmaxi si
9 pj = 1
10 return (p)
Figure 3. rcNetcorr and rcNetlap Algorithms - Rank Coherence in Networks by Enumeration.
Enumeration Methods
The ridge regression model provides an approximation solution, but if we are only interested in retrieving
the most relevant disease phenotype. We can simply go through each phenotype and compute a score
against the query gene set g for each case. Finally, the phenotype with the largest score is chosen as the
target phenotype. We propose two functions to measure rcNet for this approach,
rcNetcorr(g˜, p˜,A) = corr(Ap˜, g˜), (9)
rcNetlap(g˜, p˜,A) = −
∑
i,j
Ai,j(p˜i − g˜j)2. (10)
Function rcNetcorr simply uses the Pearson correlation coefficient to check the consistency between Ap˜
and g˜, similar to the concordance score used by CIPHER [10]. Function rcNetlap checks if the neigh-
boring genes and phenotypes in the association network are assigned similar scores, and the smaller the
disagreement, the higher the relevance. This enumeration strategy is similar to CIPHER [10]. The ad-
vantages are the conceptual simplicity and the optimality of the exact solution. The disadvantages are
the computational cost incurred by the repeated calculation of the association score for each possible
combination of the individual phenotypes, and the inflexibility to extend to more general problem of
finding multiple target phenotypes. The full algorithm to solve the two enumeration models is given in
Fig. 3. Inside the for-loop between line 3 and 7, the rcNet score is computed for each configuration of p.
The overall time complexity of this algorithm is also O(m3 + n3) if (1− β)(I− βP¯)−1 is precomputed.
Note that this is the computational cost by which we only want to retrieve one phenotype. If we want to
explore all possible configurations of p, the total cost is exponential in m.
Results
The rcNet algorithms are first compared to other methods in experiments of leave-one-out cross-validation
and a task of predicting recently discovered disease-gene associations with OMIM data. The rcNet
7algorithms are then applied to validate findings in datasets from GWAS, DNA copy number analysis,
and microarray gene expression profiling.
Preparing Networks
The disease phenotype network is an undirected graph with 5080 vertices representing OMIM disease
phenotypes, and edges with weights in [0,1]. The edge weights measure the similarity between two
phenotypes by their overlap in the text and the clinical synopsis in OMIM records, calculated by text
mining [9].
The disease-gene associations are represented by an undirected bipartite graph with edges connecting
phenotype nodes with their causative gene nodes. Two versions (May-2007 Version and May-2010 Version)
of OMIM associations were used in the experiments [1]. The May-2007 Version contains 1393 associations
between 1126 disease phenotypes and 916 genes, and the May-2010 Version contains 2469 associations
connecting 1786 disease phenotypes and 1636 genes. The May-2007 version was used in the validation
experiments on the OMIM data and the GWAS datasets, and the May-2010 version was used in the
experiments on the DNA copy number and gene expression datasets.
Two gene networks were used in the experiments. The first one was derived from the human protein-
protein interaction (PPI) network obtained from HPRD [19]. The PPI network contains 34,364 binary
undirected interactions between 8919 genes. This network was used in the experiments on the OMIM
data. A larger human functional linkage network [20] was used in the experiments on the GWAS, DNA
copy number and gene expression datasets. This network contains 24,433 genes and around 60 million
weighted edges. To reduce the computational complexity, we applied a cutoff 0.6 on the edge weights to
generate a sparser network with around 7 million weighted edges.
Comparison with Other Methods and Evaluations
The rcNet algorithms were compared with CIPHER [10] and Random Walk with Restart (label propaga-
tion) methods [13–16], since those methods reported the best performance for disease gene prioritization.
We adopted CIPHER with direct neighbor (C-DN) or shortest path (C-SP) for disease phenotype and
gene set association analysis by averaging the correlations across the genes in the query gene set. The
Random Walk algorithm described in [16] (RWR) was chosen as the label propagation method for com-
parison because it is straightforward to use the model for disease phenotype and gene set association
analysis. The two hyper-parameters α and β for rcNet were chosen from {0.1,0.5,0.9}, and a small
number κ = 10−5 was chosen for ridge regression in all experiments. The three balancing parameters
for RWR were also chosen from {0.1,0.5,0.9}. For all the methods, the results produced by the best
parameters in the leave-one-out cross-validation were reported.
In all the experiments, a query gene set was used to rank all the 5080 disease phenotypes. The higher
the target phenotype in the ranking, the better the performance. We measured the performance of a
method with receiver operating characteristic (ROC) score, also called area under curve (AUC). Since
we are most interested in whether the target phenotype is near the top, we report the the area under the
ROC curve up to the first 50 and 100 false positives. Another important evaluation is how well a method
selects highly coherent top-ranked genes and top-ranked phenotypes since high coherence implies a good
utilization of known associations in the model. Specifically, the top genes and phenotypes ranked by the
query gene set and the target disease phenotype are assigned largest scores in the cost functions, and
connections cancels out the large scores to give smaller penalty. To quantify the connectivity, the top-r
disease genes and the top-l disease phenotypes with known OMIM disease-gene associations are selected
to measure fold enrichment, which is calculated as k(r∗l)∗e , where k is the number of observed OMIM
associations between the r genes and the l disease phenotypes, and e is the probability of observing
a random association between a gene node and phenotype node, estimated from the density of the
OMIM disease phenotype-gene associations. Higher fold enrichment indicates higher coherence between
8Table 1. Performance comparison in leave-one-out cross-validation and new association
prediction with OMIM data. The tables report the average ROC50 and ROC100 across all the
query cases for each method.
(A) Leave-one-out cross-validation
Methods rcNet rcNetcorr rcNetlap RWR CDN CSP
ROC50 0.160 0.195 0.198 0.140 0.139 0.154
ROC100 0.206 0.254 0.257 0.193 0.197 0.195
(B) Prediction of novel disease phenotype-gene associations
Methods rcNet rcNetcorr rcNetlap RWR CDN CSP
ROC50 0.117 0.134 0.136 0.110 0.077 0.062
ROC100 0.151 0.177 0.178 0.148 0.103 0.096
top-ranked genes and disease phenotypes, i.e. highly connected with OMIM disease phenotype-gene
associations.
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Figure 4. Ranking comparison in leave-one-out cross-validation. This figure reports the number of query cases,
on which a method ranked the target disease phenotype among the top k ∈ [1,100] phenotypes.
Leave-one-out Cross-validation in OMIM
For each disease phenotype, the genes associated with the phenotype in OMIM were used as the query
gene set to retrieve the disease phenotype. Note that the associations between the query gene set and all
disease phenotypes including the target disease phenotype were removed in the experiment for leave-one-
out cross-validation. In the experiments with RWR, as suggested by [16], the disease phenotype network
was pruned by taking the 5 nearest neighbors of each node to reduce the computational complexity
in leave-one-out cross-validation. Table 1(A) reports the average ROC50 and ROC100 scores across all
the query cases in the leave-one-out cross-validation. Overall, the rcNet algorithms outperformed the
other methods. Specifically, rcNetcorr and rcNetlap achieved the best results with about 5% and 6%
better ranking compared with the best of the others. rcNet performed slightly better than RWR, while
CIPHER DN and CIPHER SP achieved lower scores. Fig. 4 shows a global comparison of the ranking
by plotting the number of query cases with the target disease phenotype ranked above a certain rank.
Clearly, the rcNet algorithms achieved better rankings at any ranking threshold in the experiments. For
example, rcNetcorr and rcNetlap ranked around 290 query cases above rank 50, while RWR and CIPHERs
9ranked around 230 query cases above the rank.
We further analyzed how the rank coherence between the rankings by the query gene set and the disease
phenotypes could affect the performance of rcNet algorithms and CIPHER. Based on the coherence
assumption, the top ranked genes and the top ranked phenotypes by the query gene set and the target
disease should be highly connected with each other by a good method. Fig. 5 compares the number of
queries that achieved a significant fold enrichment for the target disease phenotype compared with the
unrelated phenotypes. rcNet consistently identified more cases with significant fold enrichment against
CIPHER SP at all the z-score thresholds. This observation suggests that label propagation is a better
measure than shortest path to distinguish a target phenotype from unrelated ones because the information
of gene neighborhoods are better utilized. Interestingly, CIPHER DN detected much less associations
with high significance, but more cases with very high significance. For some query gene sets, which
include genes with many disease genes as direct neighbors in dense disease gene modules, the direct
gene neighbors tend to have more dense associations with the related phenotypes. However, only less
than one-third of the query gene sets are the easy cases. CIPHER DN failed to find a significant fold
enrichment for the other two-thirds. Thus, CIPHER DN is not performing well in general.
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Figure 5. Fold enrichment significance. For each query, the association fold enrichment between the top-20 genes
ranked by the query gene set and the top-20 disease phenotypes ranked by each disease phenotype is calculated. A z-score
of fold enrichment was then computed for the target disease phenotype based on the scores of the unrelated disease
phenotypes. This figure plots the number of query cases with a z-score above varying thresholds. A z-score at 1.96
corresponds to a p-value=0.05, assuming a normal distribution.
Predicting new OMIM Associations
To further evaluate how well a method can predict new disease-gene associations based on known associ-
ations, a case study was designed to predict the target disease phenotype of the new disease genes added
into OMIM between May, 2007 and May, 2010. There are 387 new disease phenotypes were annotated
in OMIM since May, 2007, excluding 11 new disease phenotypes whose disease genes have no interaction
in the gene network. In this experiment, the task is to predict the target disease phenotype of the newly
annotated disease genes, i.e. to query a set of new disease genes of a disease phenotype to retrieve the
phenotype based on the disease-gene associations in May-2007 Version. Table 1(B) reports the average
ROC50 and the ROC100 scores. rcNetcorr and rcNetlap performed the best, followed by rcNet and RWR,
10
and CIPHER DN and CIPHER SP did not produce comparable results with the other methods. A
possible reason for the worse performance of CIPHER is that the new cases are relatively under studied
compared with the other disease phenotypes, and the global information in all the networks are necessary
for an accurate inference of the associations. The results further supports the better performance of the
rcNet algorithms compared with the baselines.
Table 2. Ranking the target disease phenotype of the disease susceptibility genes
identified from GWAS. The disease categories in the first column are based on the definition in [21].
In the third column, the PubMed IDs marked with ‘*’ denote multiple GWASs for a disease/trait.
Refer to supplementary Table for the results of the full list of the GWAS cases.
Category Disease/Trait OMIM Index
Gene Set Rank by Rank by Rank by
Size rcNet rcNetcorr rcNetlap
Cancer
Prostate cancer 176807 15 2 (0.03%) 2 (0.03%) 2 (0.03%)
Breast cancer 113705 26 7 (0.1%) 51 (1%) 43 (0.8%)
Basal cell carcinoma (cutaneous) 605462 5 7 (0.1%) 189 (3.7%) 228 (4.5%)
Basal cell carcinoma (cutaneous) 604451 5 90 (2%) 202 (4%) 256 (5%)
Urinary bladder cancer 109800 1 14 (0.2%) 48 (0.9%) 60 (1.1%)
Acute lymphoblastic leukemia (childhood) 159555 3 19 (0.04%) 51 (1.0%) 45 (0.8%)
Lung cancer 211980 12 22 (0.4%) 587 (12%) 1610 (32%)
Lung adenocarcinoma 211980 6 52 (1%) 838 (16%) 1815 (36%)
Chronic lymphocytic leukemia 151430 14 57 (1%) 318 (6.3%) 306 (6%)
Neuroblastoma (high-risk) 600613 1 143 (3%) 110 (2%) 138 (3%)
Immunological
Systemic lupus erythematosus 152700 10 46 (0.9%) 178 (4%) 161 (3%)
Leprosy 246300 4 78 (1.5%) 62 (1.2%) 64 (1.3%)
Leprosy 607572 4 272 (5%) 54 (1%) 55 (1%)
Endocrine
Type 2 diabetes 125853 9 97 (2%) 718 (14%) 1912 (38%)
Type 1 diabetes 222100 26 331 (7%) 690 (13%) 191 (3.8%)
Gastrointestinal Crohns disease 266600 2 60 (1.2%) 1396 (27%) 3012 (59%)
Predicting Disease Phenotypes of Disease Susceptibility Genes from GWAS
The goal of GWAS is to discover disease susceptibility loci/genes that could be useful for assessing or
predicting an individual’s risk of disease. However, it is often challenging to assess how a set of novel
disease susceptibility genes potentially influence susceptibility in disease, especially when the set of genes
have no or little previously known disease implications, or function and pathway annotations. In this case
study, we collected new disease susceptibility genes from GWAS, whose roles in disease susceptibility are
not previously understood, and applied rcNet algorithms to predict the disease phenotype of the disease
susceptibility genes. We extracted all the disease susceptibility genes discovered in GWAS based on a
recent survey of all studies reported in the GWAS catalog as of Dec. 2010 [22]. After filtering out the genes
already included in OMIM May-2007 Version, we selected 217 diseases/traits with novel susceptibility
genes that are not associated with any disease phenotype in OMIM May-2007 Version, and 31 out of the
217 diseases/traits could be matched with OMIM phenotypes in the disease network. Subsequently, the
31 diseases/traits and their susceptibility genes were used in this experiment.
We queried the set of disease susceptibility genes of each of the 31 diseases/traits to rank the 5080
OMIM disease phenotypes. A disease/trait could be matched with multiple OMIM disease phenotypes.
We report the rank of the matched phenotype with the best ranking for each query. The ranking results
of a subset of the 31 diseases/traits are reported in table 2. Among the 31 queries, 14 cases ranked
the target diseases within top 2% (ranked within top 100). Notable examples are prostate cancer, breast
cancer, basal cell carcinoma, bladder cancer, acute lymphoblastic leukemia, systemic lupus erythematous,
and leprosy. In these cases, the rcNet algorithms ranked the target disease phenotype of the query
gene set within top 1%. Fig. 6 shows the example that rcNet accurately ranked the breast cancer
phenotypes of the breast cancer susceptibility genes, by querying with 26 novel breast cancer susceptibility
genes from GWAS. The connectivity between the top ranked disease genes and the top ranked disease
phenotypes is around 13 folds of the expected number of connections between the same numbers of
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Figure 6. Querying with breast cancer susceptibility genes from GWAS by rcNet. This
example shows how rcNet algorithm predicted the target disease phenotypes of breast cancer
susceptibility genes from GWAS. By querying with the 26 novel breast cancer susceptibility genes from
GWAS, rcNet ranked the 20 disease genes in the gene subnetwork at the top. The gene subnetwork also
includes 14 out the 26 query genes, which are connected with the top-20 genes. Similarly, the top 20
disease phenotypes ranked by OMIM114480:breast cancer disease phenotype are included in the disease
subnetwork. In this example, 5 of the 20 top-ranked disease genes are connected to 7 of the top-20
disease phenotypes given by 7 OMIM disease-gene associations, compared with the expected 0.87
association between 34 random genes and 20 random phenotypes.
random genes and phenotypes, or around 11 folds of the average number of connections given from the
phenotype ranking by the relevance to the unrelated disease phenotypes. One interesting observation is
that the target disease phenotype OMIM:113705 ‘BREAST CANCER 1 GENE; BRCA1’ is only directly
connected with two top ranked disease phenotypes, OMIM: 114480 ‘BREAST CANCER’, OMIM:151623
‘LI-FRAUMENI SYNDROME 1:LFS1’, and OMIM:‘259500: OSTEOGENIC SACROMA’, and only 5
of the 26 query genes directly interact with the top ranked disease genes with disease-gene associations.
The neighbor expansions in both the gene network and the phenotype network resulted in 4 OMIM
disease-gene associations. This observation suggests that, simply exploring the direct neighbors of the
query gene set and the target disease phenotype in the networks, a method might fail to infer disease-gene
set associations, due to the low statistical significance of the sparse connectivity between the genes and
the disease phenotypes. Specifically, in this example, the fold enrichment for 4 associations is 7.53, which
is significantly lower than the 12.35 fold enrichment obtained by rcNet. Another interesting example
is the inference of the association between leprosy and its susceptibility genes from GWAS (pubmed
20018961). In OMIM May-2007 Version, leprosy has no causative genes, and the leprosy susceptibility
genes from GWAS also have no association with any disease. The lack of known associations in both the
target disease phenotype and the get set poses a hard case that gene set enrichment analysis based on
overrepresentation will fail to reveal, but rcNet algorithms ranked Leprosy within top 2%.
In contrast to the results in cross-validation on OMIM data, rcNet produced significantly better
results in cancer, immunological, and gastrointestinal disease, compared with rcNetcorr and rcNetlap.
Interestingly, previous studies showed that disease susceptibility genes from GWAS catalog have less
modularities in the gene network compared to those of the known disease genes in OMIM, and pheno-
typically similar diseases such as immunological and gastrointestinal diseases do not tend to share their
disease genes [23, 24]. Those previous studies also implicated that due to the unique topological charac-
teristics of disease susceptibility genes discovered in GWAS, the existing network-based methods would
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fail to reveal the associations between the disease susceptibility genes and the disease. However, our
experiments suggest that, by incorporating the global topological information in the networks and the
known OMIM associations, rcNet algorithms can successfully discover the elusive associations in many
cases.
Predicting Disease Phenotypes of Genes with Copy Number Changes
In DNA copy number analysis, genes in the chromosomal regions with copy number changes are identified
as candidate disease genes. In this experiment, we applied the rcNet algorithms to predict the target
disease phenotypes of the candidate disease genes in disease susceptible copy number change regions. We
collected 13 human DNA copy number change datasets from a recent human cancer copy number study
from http://www.broadinstitute.org/tumorscape [25]. The DNA copy number measurements in the
datasets were obtained on the Affymetrix 250K Sty SNP array. The regions with copy number changes
were detected by GISTIC tool with default settings [26]. Genes in the detected copy number change
regions were used as the query gene set to predict their target disease phenotypes.
Table 3 shows the ranking results by the rcNet algorithms. rcNet ranked the target disease within top
2% for 6 of the 13 cancers and rcNetcorr ranked the target disease within top 2% for 7 of the 13 cancers.
In 9 of the cases, at least one algorithm ranked the target disease within top 100. [25] stated that more
than three-quarters of the statistically significantly altered copy number regions contain potential cancer
causing genes that are not previously validated targets of somatic copy number alternations in human
cancer. This suggests that enrichment analysis of the genes will not reveal any disease-association, but
rcNet algorithms found many associations with the network information.
Table 3. Ranking the target disease phenotypes of the candidate disease genes with copy
number changes. This experiment includes 13 human cancer copy number studies from [25].
Disease/Trait
Rank by Rank by Rank by
rcNet rcNetcorr rcNetlap
Neuroblastoma 5 13 126
Colorectal cancer 14 20 613
Renal cancer 22 14 33
Non small cell lung cancer 34 48 558
Breast cancer 68 136 521
Medulloblastoma 77 826 2007
Prostate cancer 129 127 2447
Ovarian cancer 322 73 1108
Small cell lung cancer 759 53 909
Mesothelioma 959 21 54
Gastrointestinal stromal tumor 1169 787 1679
Hepatocellular carcinoma 4241 952 1295
Glioma 4705 787 951
Predicting Disease Phenotypes of Differentially Expressed Genes
It is frequently observed that many disease susceptibility genes are not differently expressed in microarray
gene expression experiments. In this experiment, we applied rcNet algorithms to predict the target disease
of differentially expressed genes in gene expression profiles. We collected 13 human cancer microarray
gene expression dataset from GEO. Gene expression profiles were obtained on the Affymetrix HU133A
array, and normalized by RMA [27]. Standard t-test was used to identify differentially expressed genes.
The differentially expressed genes were used to query for their target diseases. To quantify how reliable
a differential expression is, the query gene nodes were initialized by the absolute values of the t-statistics
for label propagation. Table 4 reports the results of predicting the target diseases of the differentially
expressed genes. Out of the 13 cases, the rcNet algorithms could rank 7 within top 5%, and 12 within
top 10%. Although the result is only moderately encouraging, it validates the hypothesis that the
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neighboring information of the differentially expressed genes provides clue of association with the target
disease phenotype.
Table 4. Ranking the target disease of differentially expressed genes. The first column
represents the target disease of a microarray gene expression study, and the second column gives the
GEO number of the dataset.
Disease/Trait
GEO Rank by Rank by Rank by
Num. rcNet rcNetcorr rcNetlap
AML GSE9476 576 316 359
Breast cancer
GSE7390 14 49 51
GSE2034 40 130 146
GSE6532 129 151 182
GSE1456 138 102 109
GSE3494 161 709 1313
Gastric cancer GSE13911 248 298 362
Lung cancer
GSE10072 206 755 2219
E-MEXP-231 318 608 1115
GSE7670 379 1330 4002
Ovarian cancer GSE6008 414 1494 2283
Prostate cancer
E-MEXP-1327 271 1446 2057
GSE8218 900 1214 2498
rcNet WebTool
The rcNet algorithms were implemented and deployed as a general webtool for disease-gene set association
analysis at http://compbio.cs.umn.edu/dgsa_rcNet. Providing a list of query genes, a user can retrieve
the OMIM disease phenotypes ranked by their degree of association with the gene set. In Fig. 7, we
show an example of querying rcNet WebTool with the disease gene set of prostate cancer from GWAS.
In the implementation, the Laplacian scores are precomputed to improve efficiency. Currently, it takes
the server less than 5 seconds to response to a gene set query.
Figure 7. rcNet WebTool Demo. In this example, a gene set with a list of 15 genes identified as prostate cancer
susceptibility genes in GWAS was used to query rcNet WebTool. The left panel shows the settings used for query and the
right panel displays the query result.
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Discussion
Analysis of the gene sets from genome-wide high-throughput screening is a continuing challenge in many
disease studies. When the gene set is poorly annotated, enrichment analysis will fail to detect any
associations with disease phenotypes, or when the gene set contains genes in a broad range of functional
categories, enrichment analysis provides unreliable statistical significance. Statistics from OMIM (Jan
2011) show that 3745 of the 6675 disease phenotypes are still unknown for their molecular basis. Thus,
enrichment analysis will fail to find any associations between the 3745 disease phenotypes and any query
gene set. For example, in the experiments with the GWAS gene sets, rcNets algorithms ranked leprosy
(OMIM:246300 and OMIM:607572) among the top 2% phenotypes, while enrichment analysis reported
no association for the four disease susceptibility genes of leprosy. rcNet focuses on improving detection
of disease phenotype-gene set associations by integrating gene network and disease network to better
summarize sparse associations for a global comparison of all possible disease and gene set associations.
The rcNet algorithms effectively utilizes hidden information in the gene network and the disease network
with the machine learning models. First, the label propagation steps on both the gene network and the
disease network fully explore the neighborhood information of the query genes and a disease phenotype.
The relevance information is propagated from the seed nodes to their neighbors to provide a global
quantification of relevance, and the relevance scores are then utilized with all the known associations for
evaluating the association between the gene set and the disease phenotype. Thus, analysis with rcNet is
not biased by poor known annotation or the size of the query gene set. Second, compared with the other
methods that also utilizing the gene network and the disease network, rcNet is more flexible in handling
the network data because rcNet is capable of handling weighted associations and weighted edges in the
gene network and the disease network. rcNet does not rely on deciding direct neighbors or shortest path
as CIHPER or PRINCE [15]. Finally, the ridge regression model coupled with label propagation provides
an approximation of finding association between a gene set and multiple disease phenotypes, which is
difficult to achieve with enumeration-based strategies.
Despite the encouraging results of rcNet, there are also limitations. First, rcNet relies heavily on
the networks. For the cases where the gene set already has known associations with the target disease
phenotype, the network information might introduce noise to dilute the strong signal as showed in Fig.
5. Thus, rcNet is more useful for studying new diseases that have not been genetically characterized
rather than confirming well-understood diseases. Second, it is also difficult to distinguish the closely
related phenotypes from false positives, because it is possible that some of the top-ranked phenotypes
is not similar to or share any common disease genes with the target disease phenotype in the disease
network. Interpretation of these phenotypes will not be straightforward. A possible solution is to identify
subnetworks as the example in Fig. 6 and use information from the gene cluster and the phenotype
cluster for finding explanations.
rcNet is a helpful tool for oncologists to analyze disease and gene set association. Researchers can
validate their findings from high-throughput studies, especially, to validate novel associations between
complex diseases and a query gene set with no known associations. rcNet can also help identify closely
related phenotypes of the target disease of the query gene set. Since rcNet algorithms utilize both the
disease similarities and the gene interactions, some phenotypically similar disease phenotypes will be
ranked at the top. These disease phenotypes might provide additional information to investigate the
target disease in the study. In future work, we plan to extend rcNet as a more general tool that could
also infer enriched functions of a query gene set. We can build a GO function network with GO term
nodes and edges weighted by the similarity between two GO functions. The application of the rcNet
algorithm under this context will be straightforward.
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